Publications

5674 Results

The selenium and vitamin E cancer prevention trial (SELECT): Southwest Oncology Group Study

Authors
EA Klein;SM Lippman;P Goodman;MS Lucia;IM Thompson;LG Ford;HL Parnes;LM Minasian;JM Gaziano;JL Hartline
Journal / Conference
ASCO 2009 Genitourinary Cancers Symposium, abstract #1
Year
2009
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with enoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group study

Authors
AD Tiersten;PY Liu;HO Smith;SP Wilczynski;WR Robinson;M Markman;JP Fruehauf;DS Alberts
Journal / Conference
Western Association of Gynecologic Oncologists (WAGO) Annual Meeting, poster presentation
Year
2009
Research Committee(s)
Gynecologic
Study Number(s)
S0009

Role of T-cell immunity to embryonal stem (ES) cell antigen SOX2 in the progression of myeloma

Authors
MV Dhodapkar;V Bolejack;J Shaughnessy;P Matthews;R Pickering;P Qu;A Hoering;J Crowley;B Barlogie
Journal / Conference
Journal of Clinical Oncology 27:15s, abst.#8522
Year
2009
Research Committee(s)
Myeloma
Study Number(s)
S0120

KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536

Authors
PC Mack;WS Holland;M Redman;P Lara;LJ Snyder;FR Hirsch;WA Franklin;ES Kim;RS Herbst;DR Gandara
Journal / Conference
Journal of Clinical Oncology 27:15s, abst. #8022
Year
2009
Research Committee(s)
Lung
Study Number(s)
S0342, S0536

Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP)

Authors
SM Schuetze;P Rutkowski;M Van Glabbeke;C Rankin;BP Rubin;A Lazar;M Debiec-Rychter;H Gelderblom;P Hohenberger;A Van Oosterom
Journal / Conference
Journal of Clinical Oncology 27:15s, abst. #10520
Year
2009
Research Committee(s)
Sarcoma
Study Number(s)
S0345

Carboplatin, paclitaxel, cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC), a SWOG phase II study

Authors
DR Gandara;ES Kim;RS Herbst;J Moon;M Redman;SR Dakhil;F Hirsch;PC Mack;WA Franklin;K Kelly
Journal / Conference
Journal of Clinical Oncology 27:15s, abst.#8015
Year
2009
Research Committee(s)
Lung
Study Number(s)
S0536

Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): update of Intergroup Francophone du Myeloma (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials

Authors
B Barlogie;M Attal;J Crowley;J Harousseau
Journal / Conference
Journal of Clinical Oncology 27:15s, abst. #8519
Year
2009
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): examining whether different variables govern different time segments of survival

Authors
J Crowley;V Bolejack;K Robert;K Anderson;B Barlogie
Journal / Conference
Journal of Clinical Oncology 27:15s, abst. #8599
Year
2009
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

Southwest Oncology Group S9811: a phase II study of hydroxyurea for unresectable meningioma

Authors
L Swinnen;C Rankin;EJ Rushing;HF Laura;DM Damek;GR Barger
Journal / Conference
Journal of Clinical Oncology 27:15s, abst.#2063
Year
2009
Research Committee(s)
Brain
Study Number(s)
S9811

Does quality of treatment-related harms reporting affect conclusions about superiority of treatment?

Authors
RS Mhaskar;A Kumar;H Soares;M Schell;B Djulbegovic
Journal / Conference
Journal of Clinical Oncology 27:15s, abst.#6607
Year
2009
Research Committee(s)
Multiple sites